Tilray Brands achieved record Q1 fiscal 2025 revenue of $200 million, up 13% YoY, with gross margin expanding 500 basis points to 30%. The growth was primarily driven by beverage alcohol segment revenue surging 132% to $56 million. Cannabis revenue was $61.2 million with 40% gross margin, while distribution revenue reached $68.1 million.The company reported a net loss of $34.7 million, improving 38% YoY from $55.9 million, with loss per share decreasing to $0.04 from $0.10. Adjusted EBITDA was $9.3 million compared to $10.7 million in the prior year. German medical cannabis flower revenue increased 50% following legalization.Management expressed optimism about potential regulatory changes in the U.S. cannabis industry, citing support from presidential candidates. The company launched Tilray Alternative Beverages in October to target U.S. markets with hemp-derived Delta-9 THC products, as part of its strategy to expand its CPG portfolio across cannabis, hemp and beverage categories.

Tilray Brands achieved record Q1 fiscal 2025 revenue of $200 million, up 13% YoY, with gross margin expanding 500 basis points to 30%. The growth was primarily driven by beverage alcohol segment revenue surging 132% to $56 million. Cannabis revenue was $61.2 million with 40% gross margin, while distribution revenue reached $68.1 million.The company reported a net loss of $34.7 million, improving 38% YoY from $55.9 million, with loss per share decreasing to $0.04 from $0.10. Adjusted EBITDA was $9.3 million compared to $10.7 million in the prior year. German medical cannabis flower revenue increased 50% following legalization.Management expressed optimism about potential regulatory changes in the U.S. cannabis industry, citing support from presidential candidates. The company launched Tilray Alternative Beverages in October to target U.S. markets with hemp-derived Delta-9 THC products, as part of its strategy to expand its CPG portfolio across cannabis, hemp and beverage categories.